| Cells | Cor.4U® Human iPS derived cardiomyocytes |
| Species | Human |
| Cell Source | Induced pluripotent stem (iPS) cells (caucasian) |
| Cell Format | Monolayer of pure cardiomyocytes |
| Service Content | Electrophysiological analysis |
| Delivery | A study protocol will be sent to initiate the study. |
| Timeline | Draft report: within 4 weeks. |
| Quotation |
Human Cor.4U® Mel.Cor® is an in vitro and non-invasive assay system to monitor Axiogenesis’ Cor.4U® human induced pluripotent stem (iPS) cell-derived cardiomyocytes by means of extracellular field potential recordings from microelectrode arrays (MEA).
The Cor.4U® human iPS cell-derived cardiomyocytes reveal electrophysiological properties typical for human cardiac myocytes like functional Na+, Ca2+, and K+ voltage-gated ion channels including the hERG channel and their correct modulation through e.g. ß-adrenergic or muscarinic receptors.
The combination of the Cor.4U® human cardiomycoytes with the Mel.Cor® MEA assay provides an ideal tool to assess pharmacological, safety pharmacological and toxicological effects of drug candidates on human cardiomyocytes.
Effects of substances from different compound classes tested:
| Compound class | Drug
(application) |
Effect conc. (µM)
hSC-CM |
| IKr blocker
|
E-4031
(Class III antiarhythmic) |
10 nM; fAPD+
250 nM; IB |
| Cisapride
(Prokinetic) |
100 nM; fAPD+
1 µM; IB |
|
| Dofetilide
(Class III antiarhythmic) |
10 nM, fAPD+ | |
| INa blocker | Tetrodotoxin (TTX)
(Neurotoxin) |
1 – 10 µM; NC and SD+ |
| ICa,L blocker | Nifedipine
(Anti-hypertensive) |
100 nM; fAPD–
1000 nM; BA |
| Verapamil
(Anti-hypertensive) |
0.1 µM fAPD–
1- 10 µM BA |
|
| ß-adrenergic receptor agonist | Isoproterenol
(Bronchodilator) |
1 – 10 nM; PC |
| α-adreneric
receptor agonist |
Phenylephrine
(Vasoconstrictor) |
100 nM; PC |
Table 1: Abbreviations: NC – negative chronotropic, PC – positive chronortropic, fAPD+ – fAPD prolongation, fAPD- -fAPD shortening, IB – irregular beating, BA – beating arrest, SD+ – slope duration prolongation
Advantages Cor.4U MEA
- Primary-like cardiomyocytes of human origin.
- Non-invasive test system.
- Predictive and relevant for cardiac safety pharmacology.
- Low amount of compound required.